Applications of (±)-α-Methyl-(4-carboxyphenyl)glycine ((RS)-MCPG) in Industrial Manufacturing

As an original manufacturer of (±)-α-Methyl-(4-carboxyphenyl)glycine ((RS)-MCPG), we supply high-purity material to global sectors relying on advanced chemical intermediates. The following are principal application scenarios adopted in B2B manufacturing, each illustrating real downstream use and related industrial standards.

1. Pharmaceutical Research and CNS Drug Development

Major pharmaceutical research groups use this material as an antagonist in metabotropic glutamate receptor (mGluR) pathway investigations, especially for neurological disorder preclinical models. Research laboratories dose this compound as a tool reagent in CNS drug candidate screening, supporting critical functional assays and mechanism-of-action studies. Proper handling and traceability are required due to strict regulatory guidance affecting pharmaceutical-grade intermediates at research and early clinical stages.

Industry compliance standards

• USP General Chapter <1043> Ancillary Materials for Cell, Gene, and Tissue-Engineered Products
• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• 21 CFR Part 211 US cGMP for finished pharmaceuticals (for clinical trial material)
• EMA Guideline on Specification Limits (ICH Q6A)

Typical usage ratio

• Concentrations of 0.1–10 mM in cell-based assays
• 10–100 mg per kg scale for preclinical in vivo studies
• Adjusted based on assay design and animal model requirements
• Lower concentrations for in vitro, higher for pharmacological profiling

Downstream process integration

• Weighing and dissolution in buffered solvent under controlled environment
• Incorporation into cell culture workflows
• Direct addition into live animal dosing preparations
• Batch documentation and traceability for GLP/GMP compliance

Final product types

• Pharmaceutical research reagents
• Clinical trial drug candidates (early-stage formulations)
• Functional assay kits for neuroscience R&D
• Positive and negative controls for CNS assay validation

2. Neurochemical Assay Kit Production

Diagnostic and research reagent manufacturers include (RS)-MCPG as a critical standard or control in glutamate pathway determination kits. The ingredient supports accurate evaluation of glutamatergic signaling in tissue and cell extracts. Consistent purity and conformity to analytical-grade standards remain essential for downstream quality assurance.

Industry compliance standards

• ISO 13485:2016 Medical Devices – Quality Management Systems
• CLSI EP05-A3 Precision Performance of Quantitative Measurement Procedures
• REACH Registration for EU industrial use
• RoHS Directive 2011/65/EU for presence of hazardous substances

Typical usage ratio

• Batch concentrations from 1 μM to 1 mM depending on assay sensitivity
• Formulation at 0.5%–2% w/v in control solutions
• Kit-specific levels aligned with LOD/LOQ of analytical devices
• Modified during kit optimization for standard curve linearity

Downstream process integration

• Automated dosing into lyophilization vials during kit assembly
• Blending into master control lots under ISO cleanroom conditions
• Aliquoting into unit-dose packaging
• Stability testing on finished reagent components

Final product types

• Quantitative glutamate assay kits
• Signal pathway calibration standards for neurobiological analysis
• Biochemical screening panel controls
• Laboratory proficiency test reagents

3. Custom Peptide or Protein Modification Synthesis

Contract manufacturing organizations serving biotechnological clients utilize (RS)-MCPG for side-chain modification in custom oligopeptide synthesis. This application enables site-directed addition of carboxy-functionalized analogues into bioactive peptides or synthetic proteins, with strict sequence-specific integration and purification requirements.

Industry compliance standards

• ISO 9001:2015 Quality Management Systems
• ICH Q11 Development and Manufacture of Drug Substances
• FDA 21 CFR 820 Quality System Regulation for medical device manufacturing
• Applicable client-specific raw material specifications

Typical usage ratio

• 0.5–3 mol% relative to total amino acid equivalents in SPPS
• Typically 1–5 mg per custom batch in micro-scale synthesis
• Adjusted based on target peptide chain length
• Scaled by required degree of functionalization

Downstream process integration

• Resin loading by automated synthesizer or manual coupling cycle
• F-moc or Boc chemistry incorporation depending on sequence
• Direct HPLC purification downstream of coupling/completion
• Documentation in batch records and CoA generation

Final product types

• Synthetic peptide research tools
• Side-chain modified protein standards for pharmacological studies
• Peptide mapping reference samples
• Functionalized bioconjugates for target validation

4. In Vitro Neurotoxicology Screening Reagents

Preclinical CROs and toxicology test labs rely on this compound to selectively inhibit glutamatergic signaling in in vitro toxicity studies. The material acts as a probe substance within test systems simulating CNS adverse effect mechanisms. Lot-specific documentation and residual content analysis form part of regulatory reporting processes.

Industry compliance standards

• OECD Test Guideline Series No. 487 and 490 for in vitro testing
• GLP requirements as per OECD Principles
• FDA Guidance for Nonclinical Safety Studies
• Local authority notification for chemical use in animal model laboratories

Typical usage ratio

• 0.05–2 mM applied to cell culture media
• Exposure periods of 1–48 hours per test protocol
• Concentration chosen based on endpoint cytotoxicity
• Replicate dosing aligns with standard assay layouts

Downstream process integration

• Stock solution preparation at validated concentration
• Addition to incubated well plates or culture flasks
• Parallel negative and positive control setup for data integrity
• Documentation in GLP-compliant study records

Final product types

• GLP neurotoxicity assay reports
• Regulatory toxicology data packages
• Reference inhibition panels for in vitro test kits
• High-content screening cell models

5. Academic and Governmental Neuroscience Research Supply

Public-sector institutions and academic distributors purchase this molecule for approved research grant programs, facilitating neuroscientific exploration into excitatory amino acid receptor pathways. Purchasers require stated purity and specific lot analysis for publication and cross-lab validation, especially for comparative studies involving multiple geographic sites.

Industry compliance standards

• ISO 17025:2017 General Requirements for Testing and Calibration Laboratories
• NIH Guidelines for Chemical Use in Research Facilities (US)
• Local chemical import/export notification (UN GHS compliance)
• Material safety requirements for laboratory environments

Typical usage ratio

• Solubilized to 10 μM–1 mM in aqueous buffer for lab-scale research
• Microgram to gram scale purchases for experimental tenure
• Specific concentration dictated by research protocol
• Stock solution stability tested as per published procedures

Downstream process integration

• Operator weighing and buffer dissolution in lab fume hood
• Direct application into experimental assay plates
• Experimental record inclusion for grant reporting
• Post-experiment waste management per local policy

Final product types

• Peer-reviewed research publications
• Comparative neurobiological dataset submissions
• Method validation reference materials
• Academic course laboratory reagents